Bruck Claudine 4
4 · Annovis Bio, Inc. · Filed Feb 5, 2020
Insider Transaction Report
Form 4
Bruck Claudine
Director
Transactions
- Conversion
Common Stock
2020-01-31+3,969→ 4,769 total - Conversion
Series A-1 Preferred Stock
2020-01-31−5,556→ 0 total→ Common Stock (3,969 underlying) - Conversion
Convertible Note
2020-01-31$4.80/sh−1,117$5,362→ 0 total→ Common Stock (1,117 underlying) - Purchase
Common Stock
2020-01-31$6.00/sh+800$4,800→ 800 total - Conversion
Common Stock
2020-01-31$4.80/sh+1,117$5,362→ 5,886 total
Footnotes (3)
- [F1]The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis").
- [F2]Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143.
- [F3]The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price).